Skip to main content
Caplight Logo









TRexBio

TRexBio

Public
South San Francisco, CaliforniaBiotechhttps://trex.bio/

TRexBio is now publicly traded

The data on this page reflects TRexBio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series B

Extension

Jan 27, 2026

Total Funding Raised

$219M

Company Overview

TRexBio is a biotechnology company that develops immunoregulatory medicines by mapping human tissue regulatory T cell behavior to disease processes to identify novel therapeutic targets.

Sector

Biotech

Verticals

Life Sciences

AI Layer

Application

Keywords

regulatory T cellsTregstissue-targeted therapeuticsimmune-mediated diseasesTNFR2 agonistCD30 agonistbiotech drug discoverycomputational biologyin-silico drug discoveryimmune homeostasisclinical-stage biotechdrug development pipelineprecision immunologyatopic dermatitis treatmentpharma partnering

TRexBio Comparables

Compare TRexBio with similar companies based on industry and business-model similarity.

TRexBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mozart Therapeutics
84%
Sonoma Biotherapeutics
80%
Egle Therapeutics
80%

TRexBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 27, 2026
Series BNov 13, 2024
Series A ExtensionMar 8, 2022
Series AJun 22, 2021

Key People

Founding team and executive leadership

Johnston Erwin

Chief Executive Officer

Executive Team

Brandon H.

Chief Financial Officer

Executive Team

TRexBio Investors

Notable investors and investment history

TRexBio investors
InvestorRounds
Avego ManagementSeries B, Series B Extension
Janus Henderson GroupSeries B Extension
Agent CapitalSeries B
Balyasny Asset Management L.P.Series B Extension
SV Health InvestorsSeries B, Series A, Series A Extension, Series B Extension, Seed
Alexandria Venture InvestmentsSeries B, Series A, Series A Extension, Series B Extension
Pfizer VenturesSeries B, Series A, Series A Extension, Series B Extension

Recent news

Latest coverage and updates

  • receives_financingOct 9, 2026

    TRex Bio, Inc. receives $117M in IPO financing on its debut in California, pricing below the midpoint of its expected range.

  • receives_financingOct 9, 2026

    TRex Bio, Inc. receives $220M in venture financing to date

  • goes_publicSep 18, 2026

    TRex Bio, Inc. was planning to go public on Sep 18th '26.

TRexBio Filings

Explore SEC and related filing metadata, where available.

TRexBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range56
Year Founded2018
Last FundingJan 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?